Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
Assertio Therapeutics Inc (ASRT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/22/2024: ASRT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 12.1% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/22/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.80M USD | Price to earnings Ratio - | 1Y Target Price 3.15 |
Price to earnings Ratio - | 1Y Target Price 3.15 | ||
Volume (30-day avg) 769786 | Beta 0.83 | 52 Weeks Range 0.73 - 1.80 | Updated Date 02/19/2025 |
52 Weeks Range 0.73 - 1.80 | Updated Date 02/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.94 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -54.46% | Operating Margin (TTM) -9.41% |
Management Effectiveness
Return on Assets (TTM) -1.44% | Return on Equity (TTM) -42.36% |
Valuation
Trailing PE - | Forward PE 10.04 | Enterprise Value 27803673 | Price to Sales(TTM) 0.61 |
Enterprise Value 27803673 | Price to Sales(TTM) 0.61 | ||
Enterprise Value to Revenue 0.22 | Enterprise Value to EBITDA 4.03 | Shares Outstanding 95335600 | Shares Floating 83698335 |
Shares Outstanding 95335600 | Shares Floating 83698335 | ||
Percent Insiders 2.47 | Percent Institutions 38.47 |
AI Summary
Assertio Therapeutics Inc. (ASRT) - Comprehensive Overview
Company Profile:
History: Assertio Therapeutics Inc. (ASRT) was founded in 2006 and is headquartered in San Francisco, California. The company focuses on developing and commercializing innovative therapies for central nervous system (CNS) disorders, including epilepsy, anxiety, and depression. ASRT has a rich history of research and development, with a pipeline of potential treatments for various CNS conditions.
Business Areas: Assertio's core business areas include:
- Developing and commercializing branded CNS therapies.
- Acquiring and licensing late-stage CNS product candidates.
- Out-licensing certain legacy products to focus on CNS therapies.
Leadership: ASRT's leadership team comprises experienced individuals with expertise in drug development, commercialization, and finance. Key leaders include:
- Peter Keeling, Chief Executive Officer.
- Greg S. D'Avino, Chief Financial Officer.
- David I. Michelson, M.D., Chief Medical Officer.
Top Products and Market Share:
Top Products: Assertio's top products include:
- SYMPAZAN: This once-daily treatment for epilepsy is ASRT's flagship product.
- QUELIMINE: An extended-release formulation of topiramate used for epilepsy.
- SPRIX: This intranasal spray is FDA-approved for the treatment of fibromyalgia and chronic pain.
Market Share: ASRT holds a significant market share in the US epilepsy market with SYMPAZAN. However, it faces competition from established players like AbbVie and UCB. The company's market share in other therapeutic areas is less significant.
Total Addressable Market (TAM): The global market for CNS disorders is vast, estimated to be worth over $150 billion in 2023. This includes treatments for epilepsy, anxiety, depression, and other neurological conditions.
Financial Performance:
Revenue: Assertio's revenue has been relatively stable over the past few years, primarily driven by SYMPAZAN sales.
Profitability: The company's net income is volatile, reflecting research and development expenses and marketing investments.
Cash Flow: ASRT's cash flow is positive, indicating its ability to generate sufficient cash from operations to fund its activities.
Balance Sheet: The company has a solid balance sheet with minimal debt.
Dividends and Shareholder Returns:
Dividends: ASRT does not currently pay dividends.
Shareholder Returns: The company's stock price has been volatile, with a negative total shareholder return over the past year.
Growth Trajectory:
Historical Growth: ASRT's historical growth has been mainly driven by SYMPAZAN sales.
Future Growth: The company's future growth depends on the success of its pipeline candidates and its ability to expand its market share for existing products.
Market Dynamics:
Industry Trends: The CNS market is experiencing significant growth, driven by factors such as the aging population and rising awareness of mental health issues.
Demand-Supply Scenario: The demand for CNS therapies is expected to continue growing, while the supply of new therapies remains limited.
Technological Advancements: Technological advancements are playing a crucial role in developing new and more effective treatments for CNS disorders.
Competitors: Key competitors of ASRT include:
- AbbVie (ABBV)
- UCB (UCBJF)
- Lundbeck (LUN)
- Sunovion Pharmaceuticals (SNOV)
- Eton Pharmaceuticals (ETON)
Potential Challenges and Opportunities:
Challenges: ASRT faces challenges such as competition from established players, regulatory hurdles, and the high cost of developing new therapies.
Opportunities: The company has opportunities to expand its market share with existing products, launch new pipeline candidates, and enter new therapeutic areas.
Recent Acquisitions: No acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Overall, the AI-based fundamental rating for ASRT is 7 out of 10. This rating considers the company's strong product portfolio, market position in the epilepsy space, and potential for future growth. However, it also acknowledges the challenges posed by competition and the need for successful pipeline development.
Sources and Disclaimers:
Sources used for data and analysis include:
- Assertio Therapeutics Inc. website (https://www.assertiotx.com/)
- Yahoo Finance (https://finance.yahoo.com/)
- SEC filings (https://www.sec.gov/)
Disclaimer: This information should not be considered financial advice. Investors should conduct thorough research and consult with a financial professional before making investment decisions.
Conclusion:
Assertio Therapeutics Inc. is a promising company in the CNS space with a strong product portfolio and potential for future growth. However, investors should consider the company's challenges and competition before making investment decisions.
About Assertio Therapeutics Inc
Exchange NASDAQ | Headquaters Lake Forest, IL, United States | ||
IPO Launch date 1997-11-05 | CEO & Director Mr. Brendan P. O'Grady | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 53 | Website https://www.assertiotx.com |
Full time employees 53 | Website https://www.assertiotx.com | ||
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.